⁍ The study is expected to enroll up to 10,000 participants aged between 18 and 84 years.

---

⁍ Data from the trial will support regulatory submissions for license in the UK, EU and other countries.

---

⁍ The company has previously said it expects to file for U.S. approval of the vaccine in December.

---

– An experimental vaccine designed to fight a deadly virus has begun a late-stage clinical trial in the UK. Novavax Inc. says the trial of its vaccine for coronavirus, or COVID-19, is expected to enroll up to 10,000 people between the ages of 18 and 84, Reuters reports. The vaccine has already been tested in a small, early-stage clinical trial and is expected to be submitted for regulatory approval in the UK, EU, and other countries. The company says it could produce up to 2 billion doses of the vaccine per year once its production capacity is increased to 2 billion doses per year by mid- 2021. Novavax said it could produce up to 2 billion annualized doses once all capacity is brought online by mid-2021. The company said it could produce up to 2 billion annualized doses once all capacity is brought online by mid- 2021. Novavax is among global drugmakers racing to develop a vaccine for COVID-19, for which there are no current treatments or vaccines approved. Reuters reported on Wednesday that the EU was close to concluding preliminary talks with the company for its potential COVID-19 shot. Meanwhile, Britain recorded its highest number of daily cases of COVID-19 on Thursday, 6,634. Meanwhile, Britain recorded a second wave of infections sweeping through the country but also a much higher level of testing than during the first wave.